Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of participants at baseline in the single dose study

From: Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection

Parameters (Unit) Statistics/Category Single Dose Study
   Placebo Ferroquine
   (N = 10) 400 mg (N = 6) 800 mg (N = 6) 1200 mg (N = 6) 1400 mg (N = 6) 1600 mg (N = 6)
Age (years) Mean (SD) 30.5 (9.4) 32.0 (4.4) 31.2 (6.1) 30.5 (8.8) 24.3 (6.3) 26.5 (4.0)
  Min - Max 18 - 44 27 - 37 22 - 38 20 - 42 18 - 34 19 - 30
Height (cm) Mean (SD) 167.3 (8.7) 168.8 (7.0) 168.7 (3.9) 166.2 (7.4) 172.7 (6.7) 164.3 (5.0)
  Min - Max 147 - 176 160-176 163-174 154-174 163 - 183 157 - 172
Weight (kg) Mean (SD) 66.0 (7.8) 62.8 (9.3) 64.7 (3.6) 62.7 (8.5) 65.2 (3.5) 60.6 (5.2)
  Min - Max 55 - 78 50-71 58-59 52-75 61 - 70 57 - 71
BMI (kg/m 2 ) Mean (SD) 23.59 (2.40) 21.92 (1.85) 22.77 (1.61) 22.65 (1.83) 21.92 (1.25) 22.48 (0.88)
  Min - Max 20.1-27.6 19.5-24.3 19.8-24.5 19.6-24.8 19.7 - 23.0 21.9 - 24.0
BSA (m 2 ) Mean (SD) 1.74 (0.14) 1.72 (0.16) 1.74 (0.05) 1.70 (0.15) 1.74 (0.14) 1.78 (0.08)
  Min - Max 1.5 - 1.9 1.5 - 1.8 1.7 - 1.8 1.5 - 1.9 1.5 - 1.9 1.7 - 1.9
HR (bpm) Mean (SD) 50.9 (6.9) 56.3 (3.7) 54.4 (5.9) 53.3 (9.3) 56.8 (6.6) 54.6 (9.3)
  Min - Max 42 - 67 51 - 61 46 - 63 41 - 62 47 - 66 44 - 66
QTc B (ms) Mean (SD) 374.7 (19.6) 378.9 (20.6) 374.0 (11) 368.3 (16.9) 369.4 (28.9) 371.3 (20.6)
  Min - Max 347 - 405 346 - 405 362 - 392 337 - 388 327 - 408 334 - 396
QTc F (ms) Mean (SD) 386.5 (22.1) 384.0 (19.3) 380.5 (9.3) 376.9 (13.5) 373.4 (26.7) 378.4 (20.8)
  Min - Max 357 - 416 350 - 403 363 - 389 356 - 391 341 - 416 353 - 409
  1. NOTE: BMI: Body Mass Index; BSA: Body Surface Area; HR: Heart Rate; QTc (Bazett Fridericia); N: Count of patients; SD: standard deviation; Min: minimum; Max: maximum